Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus Depo-Provera for prevention of endometrial cancer in women with Lynch syndrome

Cancer Prevention Research

Volumn 6, Issue 8, 2013, Pages 774-781

  Lu, Karen H ^a   Loose, David S ^b   Yates, Melinda S ^a   Nogueras Gonzalez, Graciela M ^a   Munsell, Mark F ^a   Chen, Lee May ^c   Lynch, Henry ^e   Cornelison, Terri ^f   Boyd Rogers, Stephanie ^a   Rubin, Mary ^c   Daniels, Molly S ^a   Conrad, Peggy ^d   Milbourne, Andrea ^a   Gershenson, David M ^a   Broaddus, Russell R ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CREIGHTON UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ETHINYLESTRADIOL PLUS NORGESTREL; LOOVRAL; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; ORAL CONTRACEPTIVE AGENT; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; FAMILIAL CANCER; FEMALE; GENE EXPRESSION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HISTOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POPULATION RISK; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RISK REDUCTION; SINGLE DRUG DOSE; TRANSVAGINAL ECHOGRAPHY; TREATMENT RESPONSE;

EID: 84883806253     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0020     Document Type: Article

References (27)

1. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81:214-8. (Pubitemid 29144749)
2. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105-10. (Pubitemid 27033972)
3. Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001;19:4074-80. (Pubitemid 32976695)
4. Boks DE, Trujillo AP, Voogd AC, Morreau H, Kenter GG, Vasen HF. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 2002;102:198-200. (Pubitemid 35168036)
5. Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med 1980;302:551-4. (Pubitemid 10184280)
6. Deng L, Broaddus RR, McCampbell A, Shipley GL, Loose DS, Stancel GM, et al. Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer. Clin Cancer Res 2005;11:8258-64. (Pubitemid 41746935)
7. Deng L, Shipley GL, Loose-Mitchell DS, Stancel GM, Broaddus R, Pickar JH, et al. Coordinate regulation of the production and signaling of retinoic acid by estrogen in the human endometrium. J Clin Endocrinol Metab 2003;88:2157-63. (Pubitemid 36553112)
8. McCampbell AS, Broaddus RR, Loose DS, Davies PJA. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res 2006;12:6373-8. (Pubitemid 44799707)
9. McCampbell AS, Walker CL, Broaddus RR, Cook JD, Davies PJA. Developmental reprogramming of IGF signaling and susceptibility to endometrial hyperplasia in the rat. Lab Invest 2008;88:615-26. (Pubitemid 351733276)
10. Nabilsi NH, Broaddus RR, McCampbell AS, Lu KH, Lynch HT, Chen LM, et al. Sex hormone regulation of survivin gene expression. J Endocrinol 2010;207:237-43.
11. Westin SN, Broaddus RR, Deng L, McCampbell A, Lu KH, Lacour RA, et al. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Cancer Biol Ther 2009;8:2126-35.
12. Carmon KS, Loose DS. Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells. Mol Cancer Res 2008;6:1017-28.
13. Carmon KS, Loose DS. Wnt7a interaction with Fzd5 and detection of signaling activation using a split eGFP. Biochem Bioph Res Co 2008;368:285-91.
14. Nabilsi NH, Broaddus RR, Loose DS. DNA methylation inhibits p53-mediated survivin repression. Oncogene 2009;28:2046-50.
15. Bell SC, Jackson JA, Ashmore J, Zhu HH, Tseng L. Regulation of insulin-like growth factor-binding protein-1 synthesis and secretion by progestin and relaxin in long term cultures of human endometrial stromal cells. J Clin Endocrinol Metab 1991;72:1014-24. (Pubitemid 21921800)
16. Gao JG, Mazella J, Tseng L. Activation of the human IGFBP-1 gene promoter by progestin and relaxin in primary culture of human endometrial stromal cells. Mol Cell Endocrinol 1994;104:39-46. (Pubitemid 24233818)
17. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261-9. (Pubitemid 43113031)
18. Yin H, Mittal K. Incidental findings in uterine prolapse specimen: frequency and implications. Int J Gynecol Pathol 2004;23:26-8. (Pubitemid 38018233)
19. Frick AC, Walters MD, Larkin KS, Barber MD. Risk of unanticipated abnormal gynecologic pathology at the time of hysterectomy for uterovaginal prolapse. Am J Obstet Gynecol 2010;202:507 e1-4.
20. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54. (Pubitemid 37328886)
21. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999;113:1076-81. (Pubitemid 30013356)
22. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer J Int Du Cancer 2001;95:92-5. (Pubitemid 32187079)
23. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, et al. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999;17:2100-4. (Pubitemid 29318841)
24. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-34. (Pubitemid 30064984)
25. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003;116:2627-34. (Pubitemid 36857216)
26. Mishell DR, Elhabash MA, Good RG, Moyer DL. Contraception with an injection progestin-a study of its use in postpartum women. Am J Obstet Gynecol 1968;101:1046-53.
27. Ober WB. Effects of oral and intrauterine administration of contraceptives on uterus. Hum Pathol 1977;8:513-27. (Pubitemid 8216849)